NEUROCRINE BIOSCIENCES INC (NBIX) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $100.00K; Additional Paid in Capital, Common StockUSD $2.96B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $5.10M.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $100.00K; Additional Paid in Capital, Common StockUSD $2.82B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $400.00K.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $100.00K; Additional Paid in Capital, Common StockUSD $2.79B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $13.10M.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $100.00K; Additional Paid in Capital, Common StockUSD $2.70B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $13.20M.
NEUROCRINE BIOSCIENCES INC Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Treasury Stock, Retired, Par Value Method, Amount USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Treasury Stock Acquired, Average Cost Per Share USD/shares | Additional Paid in Capital USD | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt USD | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $100.00K | $2.96B | $5.10M | $724.00M | $3.69B | (m) | 3 month · $65.00M 6 month · $122.20M | (m) | (m) | (m) | (m) |
| 2026-03-31 | $0.00 | $100.00K | $2.82B | $400.00K | $589.60M | $3.41B | (m) | 3 month · $57.20M | (m) | (m) | (m) | (m) |
| 2025-12-31 | $0.00 | $100.00K | $2.79B | $13.10M | $447.70M | $3.25B | (m) | 12 month · $217.90M | (m) | (m) | (m) | (m) |
| 2025-09-30 | $0.00 | $100.00K | $2.70B | $13.20M | $294.00M | $3.00B | 3 month · $0.00 9 month · $227.20M | 3 month · $53.70M 9 month · $159.30M | 3 month · 0.00 9 month · 127.31 | (m) | (m) | (m) |
| 2025-06-30 | $0.00 | $100.00K | $2.60B | $12.50M | $84.50M | $2.69B | 3 month · $17.70M 6 month · $227.20M | 3 month · $52.80M 6 month · $105.60M | 3 month · 119.36 6 month · 127.31 | (m) | (m) | (m) |
| 2025-03-31 | $0.00 | $100.00K | $2.53B | $9.00M | $-5.30M | $2.54B | 3 month · $209.50M | 3 month · $52.80M | (m) | (m) | (m) | (m) |
| 2024-12-31 | $0.00 | $100.00K | $2.55B | $5.80M | $29.20M | $2.59B | (m) | 12 month · $195.50M | (m) | (m) | (m) | (m) |
| 2024-09-30 | $0.00 | $100.00K | $2.62B | $14.50M | $81.10M | $2.72B | 3 month · $0.00 9 month · $0.00 | 3 month · $41.50M 9 month · $129.10M | 3 month · 0.00 9 month · 0.00 | (m) | (m) | (m) |
| 2024-06-30 | $0.00 | $100.00K | $2.56B | $2.50M | $-48.70M | $2.51B | 3 month · $0.00 6 month · $0.00 | 3 month · $43.10M 6 month · $87.60M | 3 month · 0.00 6 month · 0.00 | (m) | (m) | (m) |
| 2024-03-31 | $0.00 | $100.00K | $2.50B | $3.30M | $-113.70M | $2.39B | 3 month · $0.00 | 3 month · $44.50M | (m) | (m) | (m) | (m) |
| 2023-12-31 | $0.00 | $100.00K | $2.38B | $7.00M | $-157.10M | $2.23B | (m) | 12 month · $194.30M | (m) | (m) | (m) | (m) |
| 2023-09-30 | $0.00 | $100.00K | $2.31B | $-1.70M | $-304.80M | $2.00B | (m) | 3 month · $47.80M 9 month · $156.20M | (m) | (m) | (m) | (m) |
| 2023-06-30 | $0.00 | $100.00K | $2.24B | $-1.10M | $-387.90M | $1.85B | (m) | 3 month · $68.50M 6 month · $108.40M | (m) | (m) | (m) | (m) |
| 2023-03-31 | $0.00 | $100.00K | $2.17B | $-2.70M | $-483.40M | $1.68B | (m) | 3 month · $39.90M | (m) | (m) | (m) | (m) |
| 2022-12-31 | $0.00 | $100.00K | $2.12B | $-7.90M | $-406.80M | $1.71B | (m) | 12 month · $173.10M | (m) | (m) | (m) | (m) |
| 2022-09-30 | $0.00 | $100.00K | $2.05B | $-14.00M | $-495.80M | $1.54B | (m) | 3 month · $43.10M 9 month · $129.60M | (m) | (m) | (m) | (m) |
| 2022-06-30 | $0.00 | $100.00K | $2.00B | $-12.20M | $-564.30M | $1.42B | (m) | 3 month · $49.50M 6 month · $86.50M | (m) | (m) | (m) | (m) |
| 2022-03-31 | $0.00 | $100.00K | $1.95B | $-9.30M | $-547.40M | $1.39B | (m) | 3 month · $37.00M | (m) | (m) | (m) | (m) |
| 2021-12-31 | $0.00 | $100.00K | $2.01B | $-1.70M | $-635.80M | $1.37B | (m) | 12 month · $134.20M | (m) | (m) | (m) | (m) |
| 2021-09-30 | $0.00 | $100.00K | $1.97B | $400.00K | $-628.50M | $1.35B | (m) | 3 month · $37.10M 9 month · $98.60M | (m) | (m) | (m) | (m) |
| 2021-06-30 | $0.00 | $100.00K | $1.93B | $700.00K | $-651.00M | $1.28B | (m) | 3 month · $28.60M 6 month · $61.50M | (m) | (m) | (m) | (m) |
| 2021-03-31 | $0.00 | $100.00K | $1.90B | $1.00M | $-693.30M | $1.21B | (m) | 3 month · $32.90M | (m) | (m) | (m) | (m) |
| 2020-12-31 | $0.00 | $100.00K | $1.85B | $1.80M | $-725.40M | $1.13B | (m) | 12 month · $100.00M | (m) | (m) | (m) | 12 month · $47.50M |
| 2020-09-30 | $0.00 | $100.00K | $1.87B | $3.20M | $-1.07B | $804.30M | (m) | 3 month · $26.70M 9 month · $79.00M | (m) | (m) | (m) | (m) |
| 2020-06-30 | $0.00 | $100.00K | $1.84B | $4.60M | $-1.02B | $831.20M | (m) | 3 month · $29.50M 6 month · $52.30M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $100.00K | $1.80B | $-1.40M | $-1.10B | $700.30M | (m) | 3 month · $22.80M | (m) | (m) | (m) | (m) |
| 2019-12-31 | $0.00 | $100.00K | $1.77B | $1.40M | $-1.13B | $636.90M | (m) | 12 month · $75.30M | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $92.00K | $1.74B | $1.61M | $-1.17B | $574.50M | (m) | 3 month · $20.30M 9 month · $54.00M | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $92.00K | $1.70B | $645.00K | $-1.22B | $483.70M | (m) | 3 month · $17.90M 6 month · $33.70M | (m) | (m) | (m) | (m) |
| 2019-03-31 | $0.00 | $91.00K | $1.68B | $-233.00K | $-1.27B | $409.30M | (m) | 3 month · $15.80M | (m) | (m) | (m) | (m) |
| 2018-12-31 | $0.00 | $91.00K | $1.66B | $-1.93M | $-1.18B | $480.80M | (m) | 12 month · $58.10M | (m) | (m) | (m) | (m) |
| 2018-09-30 | $0.00 | $91.00K | $1.65B | $-2.06M | $-1.20B | $447.51M | (m) | 3 month · $13.07M | (m) | (m) | (m) | (m) |
| 2018-06-30 | $0.00 | $90.00K | $1.63B | $-2.81M | $-1.25B | $377.44M | (m) | 3 month · $11.85M | (m) | (m) | (m) | (m) |
| 2018-03-31 | $0.00 | $90.00K | $1.61B | $-3.70M | $-1.24B | $364.49M | (m) | 3 month · $19.88M | (m) | (m) | (m) | (m) |
| 2017-12-31 | $0.00 | $89.00K | $1.57B | $-1.85M | $-1.20B | $372.20M | (m) | 12 month · $42.52M | (m) | (m) | 12 month · $144.95M | (m) |
| 2017-09-30 | $0.00 | $88.00K | $1.55B | $-534.00K | $-1.21B | $347.51M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $0.00 | $88.00K | $1.54B | $-713.00K | $-1.19B | $345.24M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $0.00 | $88.00K | $1.38B | $-235.00K | $-1.13B | $247.14M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $0.00 | $87.00K | $1.37B | $-318.00K | $-1.06B | $314.88M | (m) | 12 month · $28.46M | (m) | (m) | (m) | (m) |
| 2016-09-30 | $0.00 | $87.00K | $1.36B | $-187.00K | $-1.01B | $351.65M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $0.00 | $87.00K | $1.36B | $-39.00K | $-974.78M | $381.04M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | $87.00K | $1.35B | $-188.00K | $-934.50M | $412.96M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $0.00 | $86.00K | $1.34B | $-977.00K | $-915.23M | $424.45M | (m) | 12 month · $28.39M | (m) | (m) | (m) | (m) |
| 2015-09-30 | $0.00 | $86.00K | $1.33B | $-609.00K | $-885.92M | $446.94M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | $0.00 | $86.00K | (m) | $-404.00K | $-851.48M | $466.94M | (m) | (m) | (m) | $1.32B | (m) | (m) |
| 2015-03-31 | $0.00 | $85.00K | (m) | $-179.00K | $-827.50M | $484.73M | (m) | (m) | (m) | $1.31B | (m) | (m) |
| 2014-12-31 | $0.00 | $76.00K | $1.04B | $-277.00K | $-826.30M | $208.70M | (m) | 12 month · $10.38M | (m) | $1.04B | (m) | (m) |
| 2014-09-30 | $0.00 | $76.00K | (m) | $-207.00K | $-806.86M | $224.04M | (m) | (m) | (m) | $1.03B | (m) | (m) |
| 2014-06-30 | $0.00 | $76.00K | (m) | $-126.00K | $-790.99M | $236.84M | (m) | (m) | (m) | $1.03B | (m) | (m) |
| 2014-03-31 | $0.00 | $76.00K | (m) | $-194.00K | $-777.61M | $247.06M | (m) | (m) | (m) | $1.02B | (m) | (m) |
| 2013-12-31 | $0.00 | $67.00K | (m) | $5.00K | $-765.76M | $120.41M | (m) | 12 month · $6.82M | (m) | $886.10M | (m) | (m) |
| 2013-09-30 | (m) | $67.00K | (m) | $-9.00K | $-755.12M | $129.29M | (m) | (m) | (m) | $884.36M | (m) | (m) |
| 2013-06-30 | (m) | $67.00K | (m) | $-44.00K | $-743.99M | $136.02M | (m) | (m) | (m) | $879.98M | (m) | (m) |
| 2013-03-31 | (m) | $67.00K | (m) | $-44.00K | $-731.75M | $144.95M | (m) | (m) | (m) | $876.68M | (m) | (m) |
| 2012-12-31 | $0.00 | $66.00K | (m) | $-2.00K | $-719.67M | $154.37M | (m) | 12 month · $5.48M | (m) | $873.98M | (m) | (m) |
| 2012-09-30 | (m) | $66.00K | (m) | $19.00K | $-729.16M | $143.31M | (m) | (m) | (m) | $872.38M | (m) | (m) |
| 2012-06-30 | (m) | $66.00K | (m) | $-143.00K | $-726.09M | $144.73M | (m) | (m) | (m) | $870.89M | (m) | (m) |
| 2012-03-31 | (m) | $66.00K | (m) | $-127.00K | $-725.58M | $143.83M | (m) | (m) | (m) | $869.48M | (m) | (m) |
| 2011-12-31 | (m) | $55.00K | (m) | $-87.00K | $-724.70M | $60.08M | (m) | 12 month · $2.92M | (m) | $784.81M | (m) | (m) |
| 2011-09-30 | (m) | $55.00K | (m) | $-159.00K | $-726.03M | $57.75M | (m) | (m) | (m) | $783.88M | (m) | (m) |
| 2011-06-30 | (m) | $55.00K | (m) | $-19.00K | $-757.41M | $25.56M | (m) | (m) | (m) | $782.93M | (m) | (m) |
| 2010-12-31 | (m) | $55.00K | (m) | $-48.00K | $-762.27M | $19.34M | (m) | 12 month · $3.13M | (m) | $781.61M | (m) | (m) |
| 2009-12-31 | (m) | (m) | (m) | (m) | (m) | $3.95M | (m) | 12 month · $5.54M | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | (m) | (m) | (m) | $36.77M | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |